A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator.

Related Articles:

• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Trying to LIMP-2 the lysosome February 8, 2021 # # # # Lysosomes are small bags of enzymes that are used to break down material inside of cells – digesting newly absorbed food or recycling old/used proteins and rubbish. Recently researchers have been discovering increasing evidence that points towards dysfunction in lysosomes as a key influential player in neurodegenerative conditions, like Parkinson’s. There are several Parkinson’s genetic risk…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• Making a strong case for GCase November 25, 2019   Novel therapies are increasing being developed to focus on specific subtypes of Parkinson’s. The hope is that if they work on one type of Parkinson’s, then maybe they will also work on others. Many of these new experimental treatments are focused on specific genetic subtypes of the condition, which involve having a specific genetic variation that increases one’s risk…
• Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
• Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
• The Ambroxol Results January 14, 2020   The new year has started with some pleasing clinical trial news for the Parkinson’s community: The results of the “Ambroxol in Disease Modification in Parkinson Disease” (AiM-PD study) have been published. This is a clinically available drug that is used for the treatment of respiratory issues, which researchers are re-purposing for Parkinson’s based on some interesting properties the drug…
• Monthly Research Review – December 2020 December 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Say it with me: Farn-e-syl-trans-fer-ase October 24, 2019 ng   Not a week goes by without some new peice of research suggesting yet another biological mechanism that could be useful in slowing or stopping Parkinson’s. This week researchers in Chicago reported that pharmacologically inhibiting a specific enzyme – farnesyltransferase – may represent a novel means of boosting waste disposal and helping stressed cells to survive. A number of…
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• Monthy research review – December 2019 December 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly Research Review – November 2019 November 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Shining a light on Parkinson’s November 7, 2019   NOTE: The information in today’s post should not be considered an endorsement of PhotoPharmics or the treatment they are proposing. The author of this blog has had no communication with the company. The information in this post is provided because the author has been asked by readers to discuss it. In October 2018, at the annual International Movement Disorders…
• That time APOE met Alpha Syn February 10, 2020    Recently two independent research groups published scientific papers providing evidence that a genetic variation associated with Alzheimer’s may also be affecting the severity of pathology in Parkinson’s. The genetic variation associated with Alzheimer’s occurs in a gene (a functional region of DNA) called ApoE, and the Parkinson’s pathology involves the clustering of a protein called alpha synuclein. Specifically, both…
• Genetics in PD – More Than What You Inherit June 18, 2019 By Hugh Johnston   Not all genetic causes of PD are inherited; some are likely associated with somatic genetic mutations.  Unfortunately, we do not have a good idea of how large the impact of somatic mutation is in PD, nor do we have an effective test to identify the mosaic of somatic mutations in any given patient.  It is good…
• Genetics in PD – More Than What You Inherit June 18, 2019 By Hugh Johnston   Not all genetic causes of PD are inherited; some are likely associated with somatic genetic mutations.  Unfortunately, we do not have a good idea of how large the impact of somatic mutation is in PD, nor do we have an effective test to identify the mosaic of somatic mutations in any given patient.  It is good…
• Genetics in PD – More Than What You Inherit June 18, 2019 By Hugh Johnston   Not all genetic causes of PD are inherited; some are likely associated with somatic genetic mutations.  Unfortunately, we do not have a good idea of how large the impact of somatic mutation is in PD, nor do we have an effective test to identify the mosaic of somatic mutations in any given patient.  It is good…
• Genetics in PD – More Than What You Inherit June 18, 2019 By Hugh Johnston   Not all genetic causes of PD are inherited; some are likely associated with somatic genetic mutations.  Unfortunately, we do not have a good idea of how large the impact of somatic mutation is in PD, nor do we have an effective test to identify the mosaic of somatic mutations in any given patient.  It is good…
• Monthly research review – October 2019 October 31, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• 2021: Wish list January 26, 2021 # # # # Here at the Science of Parkinson’s, we don’t like making predictions – that’s a fool’s game. We would rather focus our attention on interesting ideas and trends, discussing what we hope to see happen in the future, and exploring different ways and means by which change could occur. It is done in the hope that someone…